The combination of savolitinib and durvalumab demonstrated durable activity in a phase 2 trial of patients with papillary RCC.

Researchers have demonstrated the feasibility of a morphological-based approach to interpreting spatial transcriptomic (ST) ...

Metastatic papillary renal cancer has poor outcomes, and new treatments are needed. There is a strong rationale for investigating the combination of mesenchymal epithelial transition receptor (MET) ...

After a life-threatening surgery, Lauren Torres is back to dancing thanks to the support of her medical team and therapy dogs.

ImmunityBio, Inc. , a leading immunotherapy company, today announced the U.S. Food and Drug Administration (FDA) has authorized an expanded access program (EAP) that will bring a vital alternative ...

A Waukesha County deputy is battling a "rare, aggressive cancer." Steve Lyles has been with the department for nearly 20 ...

FDA approves an expanded access program that would offer patients an alternative to Merck’s bladder cancer medication.

Checkout how this woman shared the startling story of how a stranger approached her and told her she had cancer. Alexandra ...

Developed by the Serum Institute of India, the rBCG product, which has been modified to improve its immunogenicity and safety, was evaluated in phase 1/2 clinical trials in Europe in patients with ...

Due to the ongoing shortage of BCG, gemcitabine has been increasingly used for first-line NMIBC therapy. N-803’s ability to activate natural killer and CD8+ T cells, thus the innate immune system, to ...

More than 67,000 Americans will be diagnosed with pancreatic cancer this year. Learn more about the disease and how PanCAN can help.